You are using an outdated browser. Please upgrade your browser to improve your experience and security.

AML quick facts

Learn key facts and statistics about acute myeloid leukemia (AML).

What is AML?

Types of secondary AML (sAML)

Approximately 30% of all AML cases are diagnosed as t-AML or AML-MRC.

Proper diagnosis of AML is determined by your doctor after reviewing symptoms, completing a bone marrow biopsy and blood cell count, and running certain tests.

68 years 68 years

The average age of an AML patient is 68 years old.

Risk factors and symptoms of AML

Quick Facts for AML

Want a printable copy of the information above to share or keep for your reference?

Download now


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.